v3.25.3
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Oct. 31, 2025
Oct. 31, 2024
Jul. 31, 2025
Cash flow from operating activities      
Net loss for the period $ (8,278,328) $ (5,829,276)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization 3,818 3,818  
Financial expenses, net (89,487)  
Depreciation 22,839 22,839  
Share-based compensation 294,686 266,971  
Equity losses 44,830 71,515  
Change in fair value of warrants 69,201 616,643  
Changes in working capital:      
Decrease in amounts receivable and prepaid expenses 887,860 364,935  
Decrease in accounts payable (1,154,788) (2,936,813)  
Increase in accrued expenses and other payables 494,573 464,292  
Total cash flow from operating activities (7,704,796) (6,955,076)  
Cash flows from Investing activities      
Equity investment in BC Therapeutics (75,000) (75,000)  
Total cash flow from investing activities (75,000) (75,000)  
Cash flows from financing activities      
Proceeds from exercise of warrants 293,251  
Proceeds from the issuance of shares, net of issuance costs 11,667,001  
Total cash flow from financing activities 11,960,252  
Increase (decrease) in cash and cash equivalents (7,779,796) 4,930,176  
Cash and cash equivalents at beginning of the period 10,493,808 862,089 $ 862,089
Cash and cash equivalents at end of the period $ 2,714,012 $ 5,792,265 $ 10,493,808